{"title":"The Evolving Therapeutic Landscape and Role of Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Systematic Review","authors":"R. Talukder, D. Makrakis, P. Grivas, A. Khaki","doi":"10.17925/ohr.2023.19.1.27","DOIUrl":null,"url":null,"abstract":"The therapeutic landscape in advanced urothelial carcinoma (aUC) has been rapidly evolving over the last 6 years. Enfortumab vedotin (EV) is an antibody–drug conjugate that targets Nectin-4, which is widely expressed in UC. EV is approved by the US Food and Drug Administration for patients with aUC refractory to prior therapy. EV is now being investigated in combination with other therapeutic agents, such as immune checkpoint inhibitors, both in first-line and refractory settings in aUC as well as earlier therapy settings. In this review, we summarized the role of EV in the rapidly evolving therapeutic landscape of aUC.","PeriodicalId":249239,"journal":{"name":"Oncology & Haematology","volume":"436 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology & Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/ohr.2023.19.1.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The therapeutic landscape in advanced urothelial carcinoma (aUC) has been rapidly evolving over the last 6 years. Enfortumab vedotin (EV) is an antibody–drug conjugate that targets Nectin-4, which is widely expressed in UC. EV is approved by the US Food and Drug Administration for patients with aUC refractory to prior therapy. EV is now being investigated in combination with other therapeutic agents, such as immune checkpoint inhibitors, both in first-line and refractory settings in aUC as well as earlier therapy settings. In this review, we summarized the role of EV in the rapidly evolving therapeutic landscape of aUC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
